Literature DB >> 15463794

Practical progress and new drugs for changing patterns of leishmaniasis.

P L Olliaro1, A D Bryceson.   

Abstract

The problems surrounding leishmaniasis are changing. An increase in travel, the Indian and Sudanese epidemics of visceral leishmaniasis, parasite resistance to antimony and the emergence of AIDS-related leishmaniasis have all increased the urgency for new drugs, and led to reappraisals of the old ones, as discussed here by Piero Olliaro and Anthony Bryceson.

Entities:  

Year:  1993        PMID： 15463794     DOI： 10.1016/0169-4758(93)90231-4

Source DB:  PubMed          Journal:  Parasitol Today        ISSN： 0169-4758


  33 in total

1.  Improvement of in vitro and in vivo antileishmanial activities of 2', 6'-dihydroxy-4'-methoxychalcone by entrapment in poly(D,L-lactide) nanoparticles.

Authors:  E C Torres-Santos; J M Rodrigues; D L Moreira; M A Kaplan; B Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

Review 2.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

3.  Combination therapy with indolylquinoline derivative and sodium antimony gluconate cures established visceral leishmaniasis in hamsters.

Authors:  Chiranjib Pal; Mousumi Raha; Anirban Basu; Keshab Chandra Roy; Anasuya Gupta; Monidipa Ghosh; Niranjan Prasad Sahu; Sukdeb Banerjee; Nirup Bikash Mandal; Santu Bandyopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2002-01       Impact factor: 5.191

4.  Selective effect of 2',6'-dihydroxy-4'-methoxychalcone isolated from Piper aduncum on Leishmania amazonensis.

Authors:  E C Torres-Santos; D L Moreira; M A Kaplan; M N Meirelles; B Rossi-Bergmann
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

5.  Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India.

Authors:  T K Jha; P Olliaro; C P Thakur; T P Kanyok; B L Singhania; I J Singh; N K Singh; S Akhoury; S Jha
Journal:  BMJ       Date:  1998-04-18

6.  Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis.

Authors:  H W Murray; J Hariprashad
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

7.  Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses.

Authors:  G S Nabors; J P Farrell
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response.

Authors:  E Handman; F M Symons; T M Baldwin; J M Curtis; J P Scheerlinck
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

Review 9.  Leishmaniasis treatment--a challenge that remains: a review.

Authors:  Dilvani O Santos; Carlos E R Coutinho; Maria F Madeira; Carolina G Bottino; Rodrigo T Vieira; Samara B Nascimento; Alice Bernardino; Saulo C Bourguignon; Suzana Corte-Real; Rosa T Pinho; Carlos Rangel Rodrigues; Helena C Castro
Journal:  Parasitol Res       Date:  2008-06       Impact factor: 2.289

10.  Efficacy of the tubercidin antileishmania action associated with an inhibitor of the nucleoside transport.

Authors:  J I Aoki; E H Yamashiro-Kanashiro; D C C Ramos; P C Cotrim
Journal:  Parasitol Res       Date:  2008-09-12       Impact factor: 2.289
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.